Exploring the Diverse Functional and Regulatory Consequences of Alternative Splicing in Development and Disease

M. Brandon Titus, Adeline W. Chang and Eugenia C. Olesnicky*

University of Colorado Colorado Springs, Colorado Springs, CO, United States

Alternative splicing is a fundamental mechanism of eukaryotic RNA regulation that increases the transcriptomic and proteomic complexity within an organism. Moreover, alternative splicing provides a framework for generating unique yet complex tissue- and cell type-specific gene expression profiles, despite using a limited number of genes. Recent efforts to understand the negative consequences of aberrant splicing have increased our understanding of developmental and neurodegenerative diseases such as spinal muscular atrophy, frontotemporal dementia and Parkinsonism linked to chromosome 17, myotonic dystrophy, and amyotrophic lateral sclerosis. Moreover, these studies have led to the development of innovative therapeutic treatments for diseases caused by aberrant splicing, also known as spliceopathies. Despite this, a paucity of information exists on the physiological roles and specific functions of distinct transcript spliceforms for a given gene. Here, we will highlight work that has specifically explored the distinct functions of protein-coding spliceforms during development. Moreover, we will discuss the use of alternative splicing of noncoding exons to regulate the stability and localization of RNA transcripts.

Keywords: alternative splicing, RNA localization, splicing factors, RNA binding proteins, poison exons, premature termination codon (PTC), alternative last exon (ALE)

INTRODUCTION

Alternative splicing is a fundamental mechanism that regulates eukaryotic gene expression and expands the number of possible transcript spliceforms and protein isoforms from a relatively small number of individual genes. In fact, alternative splicing is widespread among Metazoa, and it is estimated that approximately 95% of human genes exhibit alternative splicing (Wang et al., 2008). Through the process of choosing which coding exons will be maintained in a fully processed mRNA, alternative splicing has the potential to generate unique protein isoforms from a single gene that may have distinct functions or subcellular localizations from one another. However, the alternative splicing of noncoding exons, such as those of the 5′ and 3′ untranslated regions (UTRs), also generates unique spliceforms that may affect RNA export, RNA subcellular localization, stability, and translational efficacy.

To appreciate the potential that alternative splicing has for generating distinct functional gene products, it is important to recognize the extent to which alternative splicing is utilized in an organism’s life. Large transcriptomic datasets have demonstrated the differential expression of spliceforms in different tissues, developmental time points, and disease states. However, despite the
vast data showing the use of alternative splicing, there is a relative paucity of examples for how different spliceforms from the same gene have different functions. In fact, one might argue that alternative splicing is the most enigmatic aspect of the regulation of gene expression (Tress et al., 2017; Rodriguez et al., 2020). This is likely due, in part, to the fact that it is often a significant technical challenge, even with sophisticated molecular tools, to discern the functions of different spliceforms of a gene. Nonetheless, it is important for the scientific community to tackle the Herculean task of elucidating spliceform-specific functions of genes (Ule and Blencowe, 2019). An important first step is to cultivate a greater awareness of the fact that different spliceforms may have different functions. Consequently, a nonsense mutation might be a null allele of one spliceform but may not impact another spliceform at all. Thus, taking care in interpreting experimental results in the context of spliceforms is essential. Furthermore, more spliceform specific mutant strains and antibodies should be generated to facilitate comprehensive studies of isoform functions. However, it is not until a concerted effort is made to generate such tools and perform such isoform-specific studies that the role alternative splicing plays in the cell will be fully appreciated.

In this review, we will first highlight the extensive use of alternative splicing to create unique expression patterns in different tissues, sexes, and stages during an animal’s life cycle. We will then discuss how alternative splicing can impart complex regulation of gene expression, facilitate the subcellular localization of RNAs, and review evidence for distinct functions among different spliceforms for select genes.

ALTERNATIVE SPLICING FACILITATES TISSUE-, AGE- AND SEX-SPECIFIC GENE EXPRESSION

It is estimated that the human genome encodes over 1,500 RNA binding proteins (RBPs) (Gerstberger et al., 2014) that play diverse roles in RNA regulation including RNA stability, splicing, RNA localization, and other forms of RNA processing. Most RBPs are expressed within a broad range of tissues (Van Nostrand et al., 2020) and it is estimated that only 2–6% of RBPs show tissue-specific expression in humans. Nonetheless, there are tissue specific differences in the extent to which certain RNA regulatory processes, such as alternative splicing, are used. For example, both the nervous system and striated muscle have some of the highest levels of alternative splicing (Doxakis, 2014; Gerstberger et al., 2014). It is therefore not surprising that disruption of RBP function is implicated in cardiac and neurological disorders, such as amyotrophic lateral sclerosis, autism spectrum disorder, myotonic dystrophy, and cardiomyopathy (Baralle and Giudice, 2017).

One of the primary regulators of alternative splicing is a subset of RBPs identified as splicing factors. Two of the most common splicing factors are serine and arginine-rich (SR) proteins and heterogeneous nuclear ribonucleoproteins (hnRNPs) (Chen and Manley, 2009; Busch and Hertel, 2012; Fu and Ares, 2014). SR proteins are composed of two or more RNA recognition motifs and a serine-arginine rich domain that work in concert to recruit the core splicing machinery to bound splice sites, usually as a mechanism for exon inclusion (Chen and Manley, 2009; Busch and Hertel, 2012; Fu and Ares, 2014). Conversely, hnRNPs often work to block the recruitment of the core splicing machinery, resulting in exon exclusion (Chen and Manley, 2009; Busch and Hertel, 2012; Fu and Ares, 2014).

A recent survey of tissue-specific splicing showed that 95% of the tissue-specific splicing events that were supported through both proteomic and transcriptomic analyses were highly conserved and likely evolved prior to the ancestors of lobe-finned fish. However, it is important to note that the proteomic analyses utilized in this study may only detect the highest abundance proteins and may therefore not provide a comprehensive glimpse into the number of actual proteins that can be generated from the alternative splicing of a given gene. Nonetheless, the results of this study support previous findings that the brain and cardiac tissue have the highest levels of alternative splicing. In particular, the frontal cortex, fetal brain, spinal cord, and retina showed the most extensive alternative splicing. Furthermore, human coding genes are thought to have up to an average of ten different spliceforms, with approximately half of these spliceforms affecting the protein sequence (Rodriguez et al., 2020). Given the potential for alternative splicing to dramatically increase human proteomic complexity, there is a critical gap in our understanding of how different the functions are among distinct protein isoforms within a given tissue and between different tissues.

Alternative splicing also has the potential to create unique gene expression profiles between the sexes. A recent survey of gene expression across 44 human tissues in the different sexes showed that 37% of all genes have sex-biased expression in at least one tissue. However, this particular study did not examine alternative splicing signatures in these tissues or between the sexes (Oliva et al., 2020). This suggests that even more extensive sex-biased gene expression may exist in humans. Indeed, sex biased splicing has been observed in the brain, muscle and liver, and may contribute to sex differences in disease (Khramtsova et al., 2019). For example, many genes that exhibit sex biased splicing are associated with reproductive disorders or with diseases that have a sex bias in incidence (Deschênes and Chabot, 2017; Tower, 2017). Nonetheless, few splicing factors or spliceforms have been studied in detail with respect to their sex-specific functions.

In addition to tissue- and sex-specific or sex-biased alternative splicing, splicing patterns can also change during the life of an organism. In fact, changes in alternative splicing patterns and in splicing machinery are associated with senescence and aging (Deschênes and Chabot, 2017; Li et al., 2017; Wang et al., 2018). For example, there is a global increase in intron retention during aging in adult Drosophila. Yet distinct protein classes are differentially affected by this intron retention during different stages of aging, suggesting that intron retention may regulate specific aspects of the aging process. Importantly, these changes in intron retention are highly conserved in humans and mouse, as is the global increase in intron retention during aging (Adusumalli et al., 2019).
A comprehensive transcriptomic analysis of 48 different tissues from 544 human donors revealed approximately 50,000 splicing events that were correlated with age and were largely tissue specific. Importantly, changes in splicing were found in genes associated with the aging process, such as those involved in mitochondrial function, DNA repair and cell death. Moreover, substantial changes in the expression of components of splicing machinery were also detected as a function of age (Wang et al., 2018). Not surprisingly, defects in alternative splicing have also emerged as a common theme in aging-related diseases including vascular aging, accelerated aging (progeria), Alzheimer’s disease, amyotrophic lateral sclerosis, Frontotemporal lobar dementia, and myotonic dystrophy (Licatalosi and Darnell, 2006; Tazi et al., 2009; Anthony and Gallo, 2010; Lemmens et al., 2010; Strong, 2010; Mills and Janitz, 2012; Doxakis, 2014; Deschênes and Chabot, 2017). For example, intron retention is increased in brains of Alzheimer’s disease patients as compared to healthy controls (Adusumalli et al., 2019). Furthermore, the aggregation of the protein Tau, commonly associated with Alzheimer’s disease and other tauopathies, such as frontotemporal dementia with parkinsonism-17 (FTDP-17), has been shown to disrupt the localization of several known splicing factors (Jiang et al., 2021; Lester et al., 2021). Specifically, Tau oligomerization results in the mislocalization of the splicing regulators HNRNP2B1 and SRRM2 from the nucleus to the cytoplasm (Jiang et al., 2021; Lester et al., 2021). Additionally, U1 and U2 spliceosomal RNAs localize to Tau aggregates. Furthermore, transcriptomic analysis of tau deficient cell lines revealed splicing defects in 226 genes, with intron retention representing approximately 50% of these defects and an additional 25% of these splicing defects being attributed to alternate usage of first or last exons (Lester et al., 2021). Thus, aberrant alternative splicing may represent a major molecular mechanism underlying the pathophysiology of many tau-mediated neurological disorders.

The levels of expression of individual isoforms can also provide an additional layer of tissue specific gene expression. Indeed, the ratio of isoform expression has been shown to be critical to normal cell function. For example, the alternative splicing of exon 10 of microtubule-associated protein Tau (MAPT) results in Tau proteins with either 3 (3R) or 4 (4R) repeats of a microtubule-binding domain. In healthy brain tissue there is a one-to-one ratio of 4R–3R isoforms. However, disruption of this ratio in either direction has been identified as a causal factor in variations of frontotemporal dementia (FTD) (Hong et al., 1998; Stanford et al., 2003).

While transcriptomic analyses have recently started to identify large scale changes in tissue-, sex- and age-specific splicing patterns, there remains a large gap in our understanding of how these alternative spliceforms contribute to the specification and function of distinct tissues, to the establishment of sex-specific differences in organisms and to the changes that occur during the process of aging.

**ALTERNATIVE SPLICING COUPLED WITH NONSENSE MEDIATED DECAY**

While changes in alternative splicing are often thought to produce distinct functional protein isoforms, alternative splicing can also be used as a form of gene regulation. Alternative splicing coupled with nonsense-mediated decay (AS-NMD) is a mechanism of gene regulation in which alternative splicing within a pre-mRNA introduces a premature termination codon (PTC), generating transcripts targeted by nonsense-mediated decay (NMD) (Lewis et al., 2003). NMD is a critical RNA surveillance mechanism that promotes the degradation of mRNAs containing PTCs. The most common mechanism of NMD employs the use of the exon junction complex (EJC), which is a protein complex that forms at the junction of two exons in a pre-mRNA transcript. During the process of translation, the ribosome typically removes EJCs. However, when a PTC is located more than 50–55 nucleotides upstream of an EJC, the ribosome cannot remove the EJC. The PTC is bound by the proteins UPF1 and SMG1, which form a complex with eukaryotic release factors 1 and 3 (eRF1 and eRF3). This complex interacts with the EJC and ultimately recruits decapping and deadenylation enzymes which render the mRNA a target for 5′–3′ and 3′–5′ exonucleases (Figure 1; Kurosaki and Maquat, 2016; García-Moreno and Romão, 2020).

AS-NMD prevents the translation of a functional full-length protein, a process termed “regulated unproductive splicing and translation” (Lewis et al., 2003). PTCs may be introduced through usage of alternative exons containing in-frame PTCs, termed poison exons (PEs), or the skipping of essential exons which generate a downstream PTC. Additionally, PTCs can be generated through the retention of a poison intron (PI) or the use of an alternative 5′ splice site (Figure 1). PTCs may also be generated by alternative splicing in noncoding regions. For example, splicing factor SC35/serine and arginine rich splicing factor 2 (SRSF2) autoregulates its own expression through splicing events in the 3′UTR, generating an exon-exon junction downstream of the normal termination codon. The termination codon is then recognized as a PTC, targeting the transcript for NMD (Dreumont et al., 2009).

As PEs have just recently emerged as important components in regulating gene expression and maintaining homeostasis of cellular proteins, this review will report the current findings on the physiological importance of PE regulation.

**EXTENSIVE USE OF AS-NMD ACROSS METAZOA**

PEs often overlap ultraconserved elements, which are segments of DNA that are greater than 200 base pairs in length and show 100% alignment between human, mouse, and rat. This suggests that PE regulation has highly conserved functional importance (Ni et al., 2007; Saltzman et al., 2008). This is underscored by reports that NMD-candidate isoforms account for approximately one third of known human alternative isoforms (Green et al., 2003; Lewis et al., 2003). Interestingly, genes containing PEs are enriched for those involved in RNA splicing (Ni et al., 2007; Thomas et al., 2020). Indeed, most human genes encoding SR proteins are regulated by the alternative splicing of ultraconserved elements that facilitate the introduction of PEs into transcripts. Many SR proteins bind to their own pre-mRNAs
Different alternative splicing patterns can induce PTC inclusion that triggers NMD. (A) Multiple different alternative splicing events produce PTC-containing transcripts. Poison exons are cassette exons that contain an in-frame PTC and induce NMD when spliced into a transcript. The retention of a poison intron containing a PTC induces NMD. Essential exons induce NMD when skipped. An alternative poison 5′ splice site induces a frame shift that generates a PTC. For each model, splicing that generates a protein is shown on top, whereas regulatory splicing that results in AS-NMD is shown below. (B) PTC-containing mRNA is degraded by the process of NMD. Translation initiation begins to produce a polypeptide from the mRNA. Upon reaching the PTC, the proteins eRF1, eRF3, UPF1, and SMG1 are recruited to the ribosome. Recognition and interaction with a downstream EJC by UPF1 and SMG1 triggers the release of the ribosome and recruitment of SMG5, SMG6, and SMG7 to the mRNA. Decapping and deadenylation enzymes are recruited to the transcript and SMG6 cleaves the mRNA. The cleaved mRNA is then degraded by exonucleases.
and promote their own “unproductive” splicing by PE inclusion to negatively autoregulate or maintain protein levels (Lareau et al., 2007; Lareau and Brenner, 2015; Leclair et al., 2020). It is interesting to note, however, that the PEs found in SR protein-encoding genes are different from one another, suggesting that RBPs may be under strong selective pressure to acquire, retain or replace existing PEs (Lareau and Brenner, 2015). Transcriptomic sequencing of both the murine and human brain cortex revealed over 1,000 PEs that are predicted to be subject to NMD. A significant proportion of these exons are found in transcripts encoding RBPs, with 84 different RBP-encoding genes harboring NMD sensitive exons. Nonetheless, PEs are also observed among 52 genes encoding chromatin regulators, though AS-NMD regulation of chromatin regulators likely arose in the mammalian lineage (Yan et al., 2015).

In a detailed study of alternative splicing across 309 human genes, Mudge et al. determined that AS-NMD is a widespread phenomenon across vertebrates. In fact, 22% of AS-NMD events for these 309 genes are conserved in non-mammalian vertebrates, often with sequence conservation. Yet interestingly, there is more than a three-fold increase in AS-NMD events in humans compared to mice within this dataset (Mudge et al., 2011). Since this particular study only focused on 1% of the human genome, more comprehensive studies involving the entire human genome are needed to fully determine if AS-NMD is generally used at higher rates in humans as compared to other vertebrate genomes. Moreover, while certain AS-NMD events may show sequence conservation within PEs, the use of PEs and AS-NMD as a regulatory mechanism may be conserved, but not at the sequence level. For example, the RNA binding motif protein 39 (RBM39) gene, which encodes a splicing factor, has 42 annotated transcripts in humans and 24 transcript isoforms in mice. Six of these transcripts, two of which contain PEs, are conserved between mouse and human. While both of these PEs are highly conserved among mammals, one of these isoforms does not have any sequence similarity in non-mammalian vertebrate genomes (Mudge et al., 2011). Nonetheless, we have found that the Drosophila ortholog of RBM39, termed caper, also has multiple transcript isoforms, including three different poison exons. However, none of the PE sequences can be aligned to

![FIGURE 2](alternative_splicing_output.png)

**FIGURE 2 |** Alternative Splicing regulates mRNA localization. (A) Intron retention has been demonstrated to be one of the most abundant splicing events that regulates nuclear retention of mRNAs. (B) Alternative first exons with distinct 5′UTR sequences regulate bdnf mRNA localization to neurites as demonstrated in the neuron model. The gene model presented does not represent all possible alternative first exons of bdnf, but just the relative positions of the transcripts analyzed in Baj et al. (2011). (C) Large scale analysis of neurite and soma enriched alternative transcripts identifies the usage of alternative last exons as being one of the largest contributors to differential localization. More specifically, the use of distal last exons more strongly correlates with neurite localization whereas the use of proximal last exons more strongly correlates with soma localization. An example of this is shown in the neuron model.
the mouse or human genome, suggesting that the mechanism, but not the sequence, of PE-mediated regulation of caper/RBM39 expression is strongly selected for. Although, it should be noted that sequence conservation has been observed between mice and humans, with approximately 16% of non-productive exon inclusion events being conserved at the sequence level. For example, the mouse and human SCN1A genes share 96% conservation at the exon and flanking intronic regions (Lim et al., 2020).

To better characterize the extent to which AS-NMD is conserved as a mechanism for regulating gene expression, we sought to characterize the number of genes that generate PTC-containing isoforms. Previous studies have identified the conservation of AS-NMD events in humans and mice (Mudge et al., 2011; Lim et al., 2020). However, such studies have not been performed in invertebrates such as Drosophila and C. elegans. The Drosophila genomic database, FlyBase, has over 692 genes that have at least one transcript with an annotation supporting the inclusion of a PTC (Larkin et al., 2021). However, our manual curation of the annotated transcripts included in FlyBase did not demonstrate clear indication of PTC containing variants for some of these genes. One explanation is that not all transcripts, especially low-frequency exon junctions, may be included in FlyBase (Larkin et al., 2021). To provide a conservative analysis of genes containing alternatively spliced PTCs, we manually screened the list of 692 genes for readily observable isoforms containing PTCs. In this analysis, PTCs were confirmed if inclusion of an alternative exon or 5' splice site resulted in disruption of translation of a downstream exonic region that was protein coding in another transcript. Using this method, we were able to verify 374 genes with transcripts that contain PTCs with a primer binding site resulted in elongated transcript that excludes PTC, resulting in the translation of two distinct truncated proteins termed Split-ORFs, one of which effectively competes with full-length SRSF7 for binding the SRSF7 transcript (Königs et al., 2020). The binding of these short proteins results in an elongated transcript that excludes the PE but retains introns 3a, 3b, and 5 (Königs et al., 2020). These intron-containing transcripts provide binding sites that promote SRSF7 binding and oligomerization, forming nuclear bodies which may sequester different SRSF7 mRNA isoforms. The sequestration of these transcripts within the nucleus ultimately reduces the levels of translatable transcripts within the cytoplasm, as well as functional SRSF7 within the nucleus, thereby restoring normal SRSF7 protein levels (Königs et al., 2020). Other genes are also predicted to generate Split-ORFs, and these genes are enriched for those encoding RBPs including other SR proteins, such as heterogeneous nuclear ribonucleoprotein L (hnRNPL) and RBM39 (Königs et al., 2020).

The alternative splicing of PEs within other SR proteins is also regulated by an extensive autoregulatory and cross-regulatory network (Leclair et al., 2020). In an iCLIP analysis of serine and arginine rich splicing factor 3 (SRSF3) binding patterns in mouse P19 cells, SRSF3 was shown to not only autoregulate its own expression through the splicing of poison exons but was also found to cross-regulate PE usage of other SR protein-encoding genes such as SRSF2, serine and arginine rich splicing factor 5 (SRSF5), and SRSF7 (Ånkö et al., 2012). Transcriptomic analyses of induced pluripotent stem cells differentiated into various cell types including neuronal, pancreatic and lung epithelial cells indicate that PEs of SR protein-encoding transcripts are increasingly included as cells differentiate but show low inclusion within undifferentiated cells. Moreover, analyses of thirteen different human tumor expression profiles as compared to noncancerous control tissues from the Cancer Genome Atlas indicate dysregulated alternative splicing of PE-containing transcripts, suggesting that PE splicing of SR protein-encoding transcripts may be a potential therapeutic target (Leclair et al., 2020).
et al., 2020). Similarly, Thomas et al. found over 500 highly conserved PEs in HeLa and PC9 lung adenocarcinoma cells, many of which are essential for cell growth and fitness, suggestive of their roles in cancer progression (Thomas et al., 2020). The study also identified PEs that exhibit tumor-suppressor activity and revealed a link between the skipping of tumor-suppressive PE

| GO Term                                                                 | Adjusted p-value | Number of genes |
|------------------------------------------------------------------------|------------------|-----------------|
| Metal ion binding                                                      | 0.0002           | 1,328           |
| Nucleotide binding                                                    | 0.0000           | 766             |
| Ribonucleotide binding                                                | 0.0000           | 675             |
| Purine nucleotide binding                                             | 0.0000           | 670             |
| Purine ribonucleotide binding                                         | 0.0000           | 668             |
| Purine ribonucleoside triphosphate binding                             | 0.0000           | 640             |
| RNA binding                                                           | 0.0000           | 584             |
| Adenyl nucleotide binding                                             | 0.0000           | 558             |
| Adenyl ribonucleotide binding                                         | 0.0000           | 556             |
| ATP binding                                                           | 0.0000           | 534             |
| Hydrolyase activity, acting on acid anhydrides, in phosphorus-containing anhydrides | 0.0000 | 493 |
| Pyrophosphatase activity                                              | 0.0000           | 490             |
| Nucleoside-triphosphatase activity                                    | 0.0000           | 471             |
| ATPase activity                                                       | 0.0000           | 203             |
| GTPase binding                                                        | 0.0019           | 197             |
| Nucleoside-triphosphatase regulator activity                          | 0.0014           | 130             |
| mRNA binding                                                          | 0.0000           | 121             |
| GTPase regulator activity                                             | 0.0014           | 117             |
| GTPase activator activity                                             | 0.0014           | 104             |
| Methytransferase activity                                             | 0.0000           | 94              |
| Nuclease activity                                                     | 0.0026           | 90              |
| Helicase activity                                                     | 0.0000           | 84              |
| Nucleotidytransferase activity                                        | 0.0022           | 76              |
| S-adenosylmethionine-dependent methyltransferase activity             | 0.0000           | 71              |
| DNA-dependent ATPase activity                                         | 0.0000           | 57              |
| Single-stranded DNA binding                                           | 0.0008           | 54              |
| Exopeptidase activity                                                 | 0.0022           | 51              |
| N-methyltransferase activity                                          | 0.0000           | 47              |
| Exonuclease activity                                                  | 0.0026           | 46              |
| DNA helicase activity                                                 | 0.0000           | 45              |
| Single-stranded RNA binding                                           | 0.0001           | 43              |
| Hydrolyase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides | 0.0018 | 41 |
| RNA helicase activity                                                 | 0.0000           | 41              |
| Protein methyltransferase activity                                    | 0.0000           | 39              |
| 3′→5′ exonuclease activity                                            | 0.0026           | 32              |
| Exonuclease activity, active with either ribo- or deoxyribonucleic acids and producing 5′-phosphohomoesters | 0.0026 | 31 |
| NAD binding                                                           | 0.0014           | 30              |
| Aminopeptidase activity                                               | 0.0022           | 25              |
| Polyubiquitin modification-dependent protein binding                  | 0.0037           | 24              |
| 2-oxoglutarate-dependent dioxygenase activity                         | 0.0026           | 23              |
| Aminoacyl-tRNA ligase activity                                        | 0.0026           | 22              |
| 5′→3′ RNA polymerase activity                                        | 0.0022           | 22              |
| Exoribonuclease activity                                              | 0.0026           | 22              |
| Pre-mRNA binding                                                      | 0.0019           | 20              |
| Ran GTPase binding                                                    | 0.0019           | 20              |
| Positive regulation of telomerase activity                            | 0.0026           | 19              |
| 3′→5′-exoribonuclease activity                                        | 0.0026           | 19              |
| Mannosyltransferase activity                                          | 0.0007           | 18              |
| NF-kappaB binding                                                     | 0.0025           | 17              |
| Poly-pyrimidine tract binding                                         | 0.0001           | 16              |
| Poly-purine tract binding                                             | 0.0001           | 16              |
| Telomerase RNA binding                                                | 0.0015           | 15              |
| Phosphotransferase activity, for other substituted phosphate groups   | 0.0015           | 15              |
| Prenyltransferase activity                                            | 0.0015           | 13              |
| Poly(A) binding                                                       | 0.0001           | 13              |
| Mismatched DNA binding                                                | 0.0026           | 10              |
| Acyl-CoA dehydrogenase activity                                       | 0.0027           | 8               |
| Protein-arginine N-methyltransferase activity                         | 0.0027           | 8               |
| Protein prenyltransferase activity                                   | 0.0015           | 7               |
| Protein-arginine omega-N symmetric methyltransferase activity         | 0.0027           | 5               |
and poor disease prognosis in adenocarcinoma patients (Thomas et al., 2020).

The complexity of PE regulation is again highlighted by its regulation of the SR protein transformer 2 beta (Tra2β), an oncogene frequently overexpressed in various cancers. Cellular Tra2β concentration is autoregulated by the binding of full length Tra2β protein to exon splicing enhancer regions in a PE within exon two of the Tra2β transcript, promoting PE inclusion (Stoilov et al., 2004). Additionally, phosphorylation of Tra2β negatively regulates its binding to the Tra2β transcript and consequently PE

TABLE 2 | GO term analysis for AS-NMD regulated genes in mouse.

| GOTerm | Adjusted p-value | Number of genes |
|--------|-----------------|-----------------|
| RNA binding | 0.0000 | 104 |
| mRNA binding | 0.0000 | 38 |
| Ubiquitin protein ligase binding | 0.0003 | 19 |
| Pre-mRNA binding | 0.0005 | 14 |
| mRNA 3′-UTR binding | 0.0000 | 14 |
| RNA polymerase II-specific DNA-binding transcription factor binding | 0.0175 | 13 |
| Active ion transmembrane transporter activity | 0.0078 | 13 |
| Active ion transmembrane transporter activity | 0.0022 | 13 |
| Proton transmembrane transporter activity | 0.0022 | 11 |
| Single-stranded DNA binding | 0.0000 | 11 |
| Hormone receptor binding | 0.0175 | 10 |
| Single-stranded RNA binding | 0.0002 | 10 |
| Nuclease activity | 0.0310 | 10 |
| Nucleotidy transferase activity | 0.0215 | 9 |
| rRNA binding | 0.0008 | 8 |
| Helicase activity | 0.0284 | 8 |
| Ubiquitin-like protein-specific protease activity | 0.0153 | 7 |
| Translation factor activity, RNA binding | 0.0087 | 7 |
| Nuclear receptor binding | 0.0175 | 7 |
| Ribonuclease activity | 0.0310 | 7 |
| Antiporter activity | 0.0078 | 6 |
| Antiporter activity | 0.0022 | 6 |
| ATPase-coupled cation transmembrane transporter activity | 0.0022 | 6 |
| Regulatory RNA binding | 0.0000 | 6 |
| tRNA binding | 0.0168 | 5 |
| RNA helicase activity | 0.0284 | 5 |
| Poly-pyrimidine tract binding | 0.0002 | 5 |
| Poly-purine tract binding | 0.0002 | 5 |
| 3′-5′ exonuclease activity | 0.0310 | 5 |
| Exonuclease activity, active with either ribo- or deoxyribonucleic acids and producing 5′-phosphomonoesters | 0.0310 | 5 |
| Telomeric DNA binding | 0.0000 | 5 |
| Phosphatidylinositol-3-phosphate binding | 0.0208 | 4 |
| Ionotropic glutamate receptor binding | 0.0159 | 4 |
| Ubiquitin-like protein conjugating enzyme activity | 0.0195 | 4 |
| snRNA binding | 0.0164 | 4 |
| Translation elongation factor activity | 0.0087 | 4 |
| Pre-mRNA 3′-splice site binding | 0.0000 | 4 |
| Ion transmembrane transporter activity, phosphorylative mechanism | 0.0022 | 4 |
| Cholesterol transfer activity | 0.0159 | 3 |
| Hexosaminidase activity | 0.0105 | 3 |
| Intramolecular oxidoreductase activity, interconverting aldoses and ketoses | 0.0023 | 3 |
| SS-rRNA binding | 0.0008 | 3 |
| Pre-mRNA intrinsic binding | 0.0004 | 3 |
| mRNA CDS binding | 0.0004 | 3 |
| Anion:anion antiporter activity | 0.0078 | 3 |
| Sequence-specific single stranded DNA binding | 0.0000 | 3 |
| Large ribosomal subunit rRNA binding | 0.0205 | 2 |
| 5′-nucleotidase activity | 0.0281 | 2 |
| Uridyltransferase activity | 0.0156 | 2 |
| C-rich single-stranded DNA binding | 0.0034 | 2 |
| Poly(G) binding | 0.0002 | 2 |
| Voltage-gated chloride channel activity | 0.0078 | 2 |
| Regulatory region RNA binding | 0.0000 | 2 |
| NB-methyladenosine-containing RNA binding | 0.0000 | 2 |
| Positive regulation of telomerase RNA reverse transcriptase activity | 0.0000 | 2 |
| G-rich strand telomeric DNA binding | 0.0000 | 2 |
Tra2β PE is also cross-regulated by serine and arginine rich splicing factor 1 (SRSF1), SRSF3, and serine and arginine rich splicing factor 4 (SRSF4), SR proteins that decrease PE inclusion and compete with positive regulators, transformer 2 alpha (Tra2α) and Tra2β, to regulate PE usage (Leclair et al., 2020).

hnRNPs also autoregulate and cross-regulate one another by modulating PE usage (Ni et al., 2007; Saltzman et al., 2008; Rossbach et al., 2009). Intron 6 of the human HNRNPL pre-mRNA contains a highly conserved PE (exon 6A) whose inclusion is activated by HNRNPL binding. In a similar way,
HNRNPL cross-regulates the expression of its paralog heterogeneous nuclear ribonucleoprotein I like (HNRNPIL) (Rossbach et al., 2009). Additionally, the presence of hnRNP binding motifs surrounding PEs in SR protein encoding transcripts indicate that hnRNP can regulate PE inclusion and consequently the expression of SR proteins (Leclair et al., 2020). hnRNP can also regulate the inclusion of other RBPs that are not classified as either SR or hnRNP proteins. For example, the RNA DExH-box helicase 9 (DHX9) is associated with Ewing sarcoma, an aggressive cancer of the bone and soft tissue that typically affects younger adults. Higher DHX9 expression levels are correlated with worse prognosis for Ewing sarcoma patients, making DHX9 a potential cancer therapeutic target. Moreover, inclusion of a poison exon, encoded by exon 6A, within the DHX9 transcript results in a PTC which triggers DXH9 mRNA for NMD. Using an siRNA screening approach, Palombo et al. identified heterogeneous nuclear ribonucleoprotein M (HNRNP4) and SRSF3 as negative regulators of exon 6A inclusion. Importantly, knockdown of HNRNP4 or SRSF3 lowered DHX9 protein levels, decreased the viability and proliferation of an Ewing sarcoma cell line, and rendered the cells more sensitive to chemotherapeutics. Taken together, regulation of poison exon inclusion within the DXH9 transcript may be a powerful target for treatment of Ewing sarcoma (Palombo et al., 2020).

**ABERRANT PE REGULATION IS IMPLICATED IN NEUROLOGICAL DISORDERS**

Given that RBP dysfunction and aberrant splicing are increasingly associated with myriad neurological disorders and that PEs are critical for the regulation of RBP expression, it is not surprising that aberrant PE regulation is implicated in neurological disorders. For example, G-patch domain containing 8 (GPATCH8) is an RBP that interacts with splicing factors in nuclear speckles and is likely involved in pre-mRNA processing. Gpatch8 contains two PEs flanked by RBFOX sites, suggesting that PE inclusion is regulated by the RBP RBFOX (Chapman et al., 2019). Notably, Gpatch8 is the murine ortholog of human zinc finger protein 804A (ZNF804A), a nuclear protein whose dysfunction is linked to schizophrenia (Chapman et al., 2019). Moreover, RNA binding fox-1 homolog 1 (RBFOX1) has also been implicated in schizophrenia in a large genome wide association study, suggesting yet another link between PEs and neurological disorders (Pardiñas et al., 2018). Rbfox proteins also regulate PE inclusion in genes associated with neurodevelopment. Vaquero-Garcia et al. detected a previously uncharacterized brain-specific PE, exon 14, in the murine polypyrimidine tract binding protein 1 (Ptbp1) gene, which encodes a splicing factor involved in neurodevelopment. The PE is conserved in both mice and humans as well as other mammals, indicative of its functional importance. In mouse cortices, exon 14 is excluded from embryonic to P15 stages and included from P15 to adulthood, indicating that exon 14 inclusion is developmentally regulated. The authors also detected Rbfox binding sites downstream of exon 14 of Ptbp1 in both mouse and humans, suggesting that exon 14 inclusion is regulated by Rbfox. Indeed, nestin-specific Rbfox1 knockout in one-month old mice resulted in a considerable decrease in exon 14 inclusion (Vaquero-Garcia et al., 2016).

Ptbp1 itself regulates PE usage during neurogenesis. Ptbp1 suppresses the inclusion of a highly conserved mammalian PE (exonN) in the gene encoding the cytoskeleton protein filamin, alpha (Flna) (Zhang et al., 2016). Flna exonN inclusion is developmentally regulated such that it is included in adult brain tissue but excluded in neural progenitor cells (NPCs). Additionally, conditional knockout of Ptbp1 in the mouse cerebral cortex results in the increase of Flna exonN usage and premature differentiation of NPCs (Zhang et al., 2016). Thus, Ptbp1 regulation of Flna exonN usage may regulate NPC differentiation and cerebral cortex development. Importantly, Flna heterozygous null mutations in female humans are known to cause neuronal migration defects in the ventricular zone, which lead to brain malformations termed periventricular heterotopia (PVNH). Moreover, a rare intronic mutation in the Flna gene that causes inappropriate inclusion of exonN results in a more mild form of PVNH, further exemplifying the neurological consequences of aberrant alternative splicing (Zhang et al., 2016).

NOVA is a brain specific RBP that regulates alternative splicing and mRNA transport. Using cross-linking followed by immunoprecipitation and sequencing, Eom et al. (2013) identified nuclear and cytoplasmic NOVA RNA targets. GO term analysis shows that NOVA-regulated transcripts were enriched for genes with synaptic functions. Interestingly, while cytoplasmic NOVA binds its target RNAs predominantly near the 3′UTR, nuclear NOVA tends to bind its targets within introns. Moreover, nuclear NOVA regulates the alternative splicing of NMD sensitive isoforms for a number of its target RNAs. For example, NOVA suppresses the inclusion of PTC containing exon E15 in the discs large MAGUK scaffold protein 3 (Dlg3) transcript in the mouse brain. Indeed, NOVA knockout mice have a marked decrease in both the protein coding Dlg3 mRNA isoforms and Dlg3 protein levels compared to controls. These NOVA knockout mice express PTC-containing Dlg3 spliceforms that are not detected in controls. By contrast, NOVA also promotes the inclusion of a PTC containing exon (E17a) in the sodium channel, voltage-gated, type IX, alpha (Scn9a) transcript, leading to NMD of the transcript (Eom et al., 2013). Further analysis revealed that NOVA also mediates PE inclusion in syntaxin 2 (Stx2) and prevents PE inclusion in RAS protein-specific guanine nucleotide-releasing factor 1 (Rasgrf1) and solute carrier family 4 (anion exchanger), member 3 (Slc4a3) transcripts, suggesting that NOVA regulation of PE inclusion is target dependent. Interestingly, the splicing of NOVA-regulated transcripts is perturbed by seizure activity, raising the possibility that NOVA function can be modulated through electrical activity. Heterozygous NOVA mice displayed spontaneous seizures and epilepsy, and seizures also induced shifts in the subcellular localization of NOVA from nucleus to cytoplasm. Therefore, it is possible that variations in electrical activity elicit changes in
NOVA subcellular localization, and consequently, splicing of PE containing transcripts associated with epilepsy (Eom et al., 2013).

Interestingly, the incidence of PEs in seizure associated genes is not limited to NOVA. Indeed, of the ten genes that are most commonly associated with epilepsy, five have NMD sensitive exons including multiple that encode sodium channels (Aziz et al., 2021). Indeed, a recent study of developmental and epileptic encephalopathies patients uncovered five pathogenic variants of the sodium voltage-gated channel alpha subunit 1 (SCN1A) gene, which encodes a type I voltage-gated sodium channel. Importantly, the pathogenic variants, all of which have intronic lesions, promote PE (exon 20N) inclusion leading to NMD of the SCN1A transcripts, thereby lowering expression levels of the sodium channel (Carvill et al., 2018). In a different study, CRISPR/Cas9 was used to knock-in (KI) a pathogenic, PE promoting, variant of sodium channel, voltage-gated, type I, alpha (Scn1a) to generate a Dravet Syndrome (DS) mouse model (Voskobiynyk et al., 2021). Scn1a +/KI mice exhibited decreased levels of Scn1a mRNA and protein in the brain, as well as an increase in exon 20N inclusion compared to control mice. Moreover, truncated proteins were not detected, indicating that the transcripts likely were subjected to NMD (Voskobiynyk et al., 2021).

Additionally, analysis of cDNA from adult mouse tissues revealed that throughout development, the inclusion of exon 20N decreases, accompanied by the increase in overall Scn1a mRNA levels. A similar pattern was observed for sodium channel, voltage-gated, type VIII, alpha (Scn8a) (Voskobiynyk et al., 2021). Scn8a pre-mRNA contains two alternatively spliced exons, 18A and 18N. Exon 18N is a PE that is conserved in humans, mice, and fish (Fugu rubripes). Throughout the course of murine fetal brain development, transcripts containing exon 18N decrease while those containing 18A increase (Plummer et al., 1997). Additionally, analysis of cDNA from adult mouse tissues revealed that 18A containing Scn8a transcripts predominate in brain and spinal cord tissues while transcripts containing 18N are more abundant in non-neuronal tissues, indicating that the inclusion of exon 18N is regulated in a tissue-specific manner (Plummer et al., 1997). Thus, poison exon usage in Scn8a is regulated spatiotemporally to coordinate developmental neurogenesis in the mouse.

While we have primarily focused on the role of PEs in neurodevelopment and neurological disease, PE usage is also implicated in dystrophinopathies, which are characterized by progressive degeneration of skeletal muscle due to genetic lesions within the dystrophin encoding gene, DMD. DMD is one of the largest genes within the human genome, containing 79 protein-coding exons and 42 putative PEs. Importantly, an intronic pathogenic variant of the DMD gene may activate the inclusion of PEs, resulting in disease manifestation (Xie et al., 2020). While PE usage is implicated in dystrophinopathies, the pathophysiology of both myotonic dystrophy type 1 (DM1) and type 2 (DM2) is also associated with the sequestration of Muscleblind-like (MBNL) proteins to RNAs containing CUG or CCUG repeats (Sznajder and Swanson, 2019). This is further supported by the competition of RBPs MBNL1 and RBfox1 in binding the CCUG repeats, which is believed to be a reason for the milder phenotypes observed in DM2 compared to DM1. Additionally, increased expression of RBfox1 has been shown to correct splicing alterations and alleviate muscle atrophy in DM2 presenting tissues and organisms (Sellier et al., 2018). Thus, aberrant splicing is implicated in multiple different ways in dystrophinopathies.

**TARGETING OF AS-NMD PATHWAYS IN THE DEVELOPMENT OF THERAPEUTICS**

Given that aberrant PE regulation is associated with myriad diseases, the development of therapeutics specifically targeting PE containing transcripts may provide an effective strategy for treating disease. One of the more recent breakthroughs in therapeutic treatments for aberrant PE regulation is a technique called targeted augmentation of nuclear gene output (TANGO). TANGO utilizes antisense oligonucleotides (ASOs) to bind to mRNA splice sites to manipulate splicing events in target genes. The use of ASOs to manipulate transcript splicing events has been demonstrated to be effective, in a dose-dependent manner, in decreasing the expression of PTC-containing transcripts, increasing the expression of functional transcripts, and increasing protein levels of targeted genes in cell culture. Furthermore, ASOs have been demonstrated to be effective when targeting PTC inclusion from multiple splicing events including cassette exons, alternative splice sites, and poison introns (Lim et al., 2020).

TANGO has also shown promise in the treatment of disease. For example, Dravet Syndrome (DS) is one of the most common developmental and epileptic encephalopathies affecting an estimate of 20,000 individuals in the United States. DS is characterized by seizures, cognitive regression, ataxia, and increased mortality. Furthermore, individuals with DS are at high risk of sudden unexpected death in epilepsy (SUDEP). Greater than 80% of DS cases are due to mutations in the sodium voltage-gated alpha subunit 1 (SCN1A) gene, which is a subunit of the sodium channel Na+,1.1 (Han et al., 2020; Helbig and Goldberg, 2021). Furthermore, the mutation of SCN1A that is associated with DS is characterized by a 5-fold increase in expression of a PE, which results in a 50% reduction of Scn1a mRNA and Na+,1.1 protein levels (Voskobiynyk et al., 2021). However, treatment with ASOs targeting the SCN1A (ASO-22) has been demonstrated to be effective in reducing expression of the PE containing transcript, increasing the functional transcript, and increasing Na+,1.1 protein expression in human neural progenitor cells. Furthermore, ASO-22 treatment has also been shown to have promising effects in vivo. Intracerebroventricular injections in the brains of P2 WT mice resulted in an observable decrease of the PTC-containing Scn1a transcripts and an increase in the functional Scn1a transcripts up to 30 days after injection. Additionally, injection of ASO-22 in a DS mouse model increased...
longevity nearly 4-fold and reduced the incidence of tonic-clonic seizures and SUDEP while showing no significant lethality in WT mice treated with ASO-22 (Han et al., 2020).

TANGO has also been demonstrated to be effective in treating several cancers that are impacted by AS-NMD. For example, the gene encoding the splicing factor SF3B1 is commonly mutated in cancer in a manner that results in the usage of abnormal 3′ splice sites. One of the mis-spliced genes identified in multiple SF3B1-mutated cancerous cell lines including erythroleukemic (K562) and uveal melanoma (UVM) is *bromodomain containing 9* (BRD9), a component of the non-canonical BAF (ncBAF) chromatin remodeling complex. The role of *BRD9* in cancer was confirmed when knockout of *BRD9* conferred a growth advantage to UVM, cutaneous melanoma, and pancreatic cancer cells. Knockdown of *BRD9* also resulted in tumor growth, augmented melanocyte pigmentation, and decreased expression of melanocyte lineage specific genes in Melan-a cells. Additionally, knockdown of *BRD9* increased metastasis in mouse xenografts of murine melanoma or human UVM cells. Importantly, control in the *SF3B1* gene often results in the introduction of a PE. Inclusion of the PE triggers NMD, as indicated by the reduced half-life of *BRD9* mRNA and decreased expression of *BRD9* protein in cell culture. Excitingly, ASOs designed to block the inclusion of the *BRD9* poison exon was sufficient to rescue mis-splicing, increase protein levels, and suppress tumor growth in both UVM cells and mice xenografted with UVM cells. The *BRD9*-targeting ASO was also shown to be effective in tumor suppression in rectal melanoma patient-derived xenografts (Inoue et al., 2019).

Decreased *Tra2β* PE inclusion is also seen in multiple different types of tumors, including breast cancer. However, the use of splice-switching ASOs targeting an ultraconserved region of the *Tra2β* transcript promotes *Tra2β* PE inclusion and thereby decreases *Tra2β* protein levels. Treatment of breast cancer cell lines with these splice-switching ASOs reduces their proliferation and viability, underscoring the potential of targeting PE-containing transcripts as an effective cancer therapeutic strategy (Leclair et al., 2020). Taken together, TANGO is a promising therapeutic technique in treating diseases associated with AS-NMD. Furthermore, the specificity and diversity of ASO targeting allows this technique to be extended to other AS-NMD associated diseases and to different types of mutations that specifically affect PE inclusion.

**RNA LOCALIZATION**

In addition to alternative splicing regulating the stability of transcripts through AS-NMD, the use of alternative exons can also regulate the localization of RNA transcripts within a cell. Subcellular localization of RNA, proteins and protein complexes is critical for proper cellular function, as is evidenced by the fact that improper localization of RNAs and proteins can result in disease (Hung and Link, 2011; Engel et al., 2020; Abouward and Schiavo, 2021; Fernandopulle et al., 2021). While localization of proteins can occur post-translationally, mRNAs are often localized to subcellular compartments and remain translationally quiescent during transport. However, upon reaching their final destination, the mature mRNAs are locally translated. mRNA localization coupled with local translation is thought to increase thermodynamic efficiency compared to protein trafficking and provides cells with a metabolic savings by localizing highly stable mRNAs distally and translating them only when needed (Holt and Bullock, 2009; Buxbaum et al., 2015; Fernandopulle et al., 2021). These combined processes also facilitate rapid localized responses to signaling cues, such as within synapses (Holt and Bullock, 2009; Buxbaum et al., 2015). Moreover, maintaining translationally quiescent mRNAs during the process of localization can prevent ectopic interactions between proteins, thus spatially limiting protein function or preventing cellular toxicity. For example, myriad neurodegenerative disorders are correlated with the inappropriate formation of nuclear or cytoplasmic ribonucleic protein particle (RNP) aggregates that are thought to be toxic to neurons (Abouward and Schiavo, 2021; Fernandopulle et al., 2021). Furthermore, localized translation could also be used to control the local assembly of large multi-protein complexes.

RNA localization is highly prevalent across eukaryotes and has also recently been described in prokaryotes (Engel et al., 2020; Irastortza-Olaziregi and Amster-Choder, 2021). The widespread nature of RNA localization is underscored by the fact that during *Drosophila* embryogenesis nearly 70% of transcribed mRNAs are asymmetrically localized (Lécuyer et al., 2007). While it has been long established that mRNAs such as *bicoid* (*bcd*), *nanos* (*nos*), and *oskar* (*osk*), are also asymmetrically localized during *Drosophila* oogenesis, multiple maternal mRNAs have also been recently shown to be localized and locally translated within murine oocytes (Jansova et al., 2021). Additionally, many studies have shown widespread use of RNA localization within the nervous system. For example, a significant proportion of neuronal mRNAs in the rat hippocampus are enriched in neurites, as compared to the soma (Cajigas et al., 2012). Extensive RNA localization is also seen within endfeet of radial glial cells, a neural progenitor cell of the developing mammalian cortex (Pilaz et al., 2016; D’Arcy and Silver, 2020). Importantly, transcriptomic analyses of cytoplasmic and nuclear RNAs from human fetal and adult brain tissue suggest that thousands of RNAs have subcellular localization during human neurogenesis (Price et al., 2020; Zaghlool et al., 2021). Moreover, the subcellular localization patterns change significantly from prenatal to adult stages, highlighting a potential role in RNA localization regulating neurogenesis. Notably, many of the genes that show differential localization within neurons are associated with neurological disease (Price et al., 2020). While there have been efforts to understand the mechanisms and functional relevance of RNA localization, few individual RNAs have been studied within this capacity, especially relative to the number of RNAs that are known to be localized within cells.

Finally, RNA localization has been demonstrated to have functional importance. Mislocalization of multiple maternal mRNAs, such as *nos*, *bcd*, and *osk* in the *Drosophila* oocyte has long been known to cause severe embryonic segmentation patterning defects (Driever and Nüsslein-Volhard, 1988; Ephrussi et al., 1991; Gavis and Lehmann, 1992). Similarly,
mislocalization of {italics}nanos{italics} mRNA results in neuron
dysmorphogenesis in the {italics}Drosophila{italics} larval peripheral nervous
system (Brechbiel and Gavis, 2008). Many mRNAs have also been
shown to be localized to centrosomes in diverse cell types and
within many different organisms (Ryder and Lerit, 2018; Ryder
et al., 2020). Significantly, mistargeting of the centrosomally
localized mRNA {italics}centrocortin{italics} within the {italics}Drosophila{italics} embryo
results in mitotic spindle defects, disrupted nuclear division
and centriosome duplication defects (Ryder et al., 2020).

The observation that mRNA localization is prevalent, highly
conserved, and with functional importance, highlights the need to
understand the mechanisms that regulate mRNA localization.
RNA localization is often achieved using active transport
mechanisms (reviewed by Engel et al., 2020), diffusion and
trapping, as well as localized degradation of mRNAs. More
recently, the usage of alternative transcripts, via alternative
splicing, has also emerged as a regulatory mechanism for RNA
localization.

**ALTERNATIVE ISOFORMS AND LOCALIZATION**

Alternative splicing has recently emerged as an important
regulatory mechanism for mRNA localization. By selecting for
or against exons containing specific localization elements,
splicing machinery can precisely control the destination and
timing of RNA localization. Alternative splicing can impact
multiple stages of mRNA localization including both nuclear
export and subcellular localization within the cytoplasm. In a
recent survey of transcript variants in 13 human cell lines, over
8,000 genes were identified that contain transcript switches, or
variant isoforms where one was preferentially localized to the
nucleus and another was preferentially localized to the cytoplasm
(Zeng and Hamada, 2020; Figure 2). Interestingly, the only
splicing event that was significant for transcript switching
from nucleus to cytoplasm was intron retention, which
primarily signaled an mRNA to remain within the nucleus
(Zeng and Hamada, 2020; Figure 2A). In yeast, two
alternative splicing factors, G-strand binding protein (Gbp2)
and Hypothetical RNA-binding protein 1 (Hrb1), were
observed to preferentially bind intron-retaining mRNAs and
serve as a switch between mRNA degradation and nuclear
export (Hackmann et al., 2014). This suggests that the nuclear
retention of intron-retaining mRNAs could serve as a process of
quality control to ensure non-functional isoforms do not exit the
nucleus to be translated. However, it is plausible that nuclear
retention of mRNAs may serve other regulatory functions yet to
be identified. Although some alternative splicing events may
impact the nuclear-cytoplasmic shuttling of mRNA, many
alternative splicing events have been demonstrated to regulate
subcellular localization. For example, in rat hippocampal
neurons, the localization of {italics}bdnf{italics} mRNA was demonstrated to
be regulated by alternate 5′UTR elements (Baj et al., 2011;
Figure 2). All rat {italics}bdnf{italics} transcript variants contain a common
coding region. However, 22 different spliced forms are generated
through alternative splicing of different 5′UTR containing exons
and alternative polyadenylation sites within the 3′UTR (Baj et al.,
2011; Figure 2B). The visualization of spliceforms with one of
four different 5′UTR exons showed that transcripts containing
exons 1 and 4 localize within 40 μm of the soma. However,
variants containing exons 2C and 6 localize to the distal neurites
up to 70 μm from the soma (Baj et al., 2011; Figure 2B).

Although the localization of {italics}bdnf{italics} mRNA is regulated by elements in the
5′UTR, it has also been shown that differences in 3′UTR sequence
also regulate {italics}bdnf{italics} mRNA localization within neurons (An et al.,
2008). In particular, different polyadenylation sites within the
{italics}bdnf{italics} 3′UTR create a short (350 bp) transcript and a long
(2,850 bp) isoform, of which the long isoform is targeted to
dendrites of hippocampal neurons. Loss of the long 3′UTR
{italics}bdnf{italics} transcript results in dendritic morphology defects, as well
as physiological consequences. Indeed, regulation of mRNA
localization is most consistently imparted by elements in the
3′UTR (Gavis and Lehmann, 1992; Ferrandon et al., 1994;
Kislauskis et al., 1994; Mayford et al., 1996; Chang et al., 2004;
Gore et al., 2005; Jain and Gavis, 2008; Racca et al., 2010; Perry
et al., 2012; Taliaferro et al., 2016; Ciolli Mattioli et al., 2019; Bae
and Miura, 2020). For example, the fusion of the {italics}nos{italics} 3′UTR to a
lacZ translational reporter recapitulates endogenous {italics}nos{italics} mRNA
localization in {italics}Drosophila{italics} embryos (Gavis and Lehmann, 1992).
Moreover, the 3′UTR of {italics}nos{italics} is required to localize the {italics}nos
transcript to neurites of sensory neurons in {italics}Drosophila{italics} larvae
(Brechbiel and Gavis, 2008). Furthermore, fusion of the {italics}bcd
3′UTR to the {italics}nos{italics} RNA is sufficient to localize {italics}nos{italics} RNA to the
anterior pole of the {italics}Drosophila{italics} embryo, in a pattern
indistinguishable from the endogenous localization of {italics}bcd
mRNA (Gavis and Lehmann, 1992). More recently, it has been
shown that specific 3′UTR sequences are utilized to localize
transcripts in distinct patterns within the myelin sheath of the
developing zebrafish nervous system. And although different
UTR sequences can dictate distinct localization patterns within
myelin, some RNAs encoded by different genes share common
localization sequences that are sufficient to localize reporter
constructs to the myelin sheath (Yergert et al., 2021). Finally,
disruption of Pumilio-binding sites in the 3′UTRs of RNAs that
encode many distinct chemotaxis pathway components, results in
disrupted cell migration in the social amoeba {italics}Dictyostelium{italics},
further supporting widespread use of 3′UTR elements in RNA
localization (Hotz and Nelson, 2017).

One of the more recent developments in localization is the
impact of alternative last exons (ALEs), which can generate
distinct 3′UTR sequences in different spliceforms, on the
localization of mRNA isoforms. In N2A and CAD mouse
neuronal cell cultures, over 800 genes were identified that had
isoforms differentially enriched in the neurites or the soma.
Interestingly, of the isoforms analyzed, the highest frequency
splicing event of differentially localized isoforms was found to be
alternative last exons and tandem 3′UTRs, as compared to the
alternative first exon or skipped exon splicing events. In 80% of
the isoform pairs with ALEs, the selection of the distal ALE
coincided with localization to the neurites and selection of
proximal ALEs to the soma (Figure 2C). Furthermore, when
reporter genes were fused with the differentially localized ALEs,
those containing distal ALEs localized to neurites, however those
containing proximal ALEs had reduced localization to neurites. This suggests that the 3′UTR elements of the ALEs are sufficient to guide subcellular localization within neurons (Figure 2). Moreover, the bias for neurite-localized transcripts to utilize distal ALEs was also observed during the differentiation of human neural precursor cells, suggesting that the mechanism is conserved across species. Furthermore, many of the genes containing neurite-localized distal ALEs encode neurotransmitter receptors, ion channels, and trafficking proteins, suggesting that the preferential expression of distal ALEs ensures local translation of molecules necessary for proper functioning of mature neurons (Taliaferro et al., 2016). Interestingly, this trend is reversed during the reprogramming of human fibroblasts to induced pluripotent stem cells (iPSCs) and in various cancers, where there is preferential expression of proximal ALEs. This suggests that the usage of proximal ALEs may be inversely associated with cell differentiation. Furthermore, cleavage and polyadenylation (CPA) factors were identified as playing a potential role in the selection of the ALEs and tandem 3′UTRs. The depletion of CPA factor CFIM25/cleavage and polyadenylation specificity factor subunit 5 (Cpsf5) resulted in differential expression of proximal ALEs, whereas the depletion of the CPA factor cleavage stimulation factor subunit 2 tau variant (Cstf2t) resulted in differential expression of distal ALEs (Taliaferro et al., 2016). This would suggest that fine-tuned control of these CPA factors and other RBPs may regulate the shift from proximal ALE selection to distal ALE selection during neuron differentiation.

Another recent study utilized mouse embryonic stem cells (mESCs) to identify RNA isoforms that differentially localize between the soma and neurites. 593 different genes were found to have RNA isoforms with distinct 3′UTRs, generated either from ALE usage or alternative polyadenylation, that differentially localized to the soma versus neurites. Furthermore, the distinct 3′UTRs for cell division cycle 42 (CDC42) mRNAs were sufficient to localize reporter constructs to their respective compartments. Interestingly, there was also a bias for shorter 3′UTRs to be localized to neurites as compared to the soma (Gioli Mattioli et al., 2019). However, examples of long 3′UTR isoforms conferring dendritic localization have also been reported (An et al., 2008). Taken together, alternative splicing of noncoding exons may not necessarily affect protein sequence but may have very real functional consequences by regulating the subcellular localization of specific RNA transcripts.

FUNCTIONAL ISOFORMS

Thus far, we have focused on how alternative splicing can regulate RNA localization and stability. However, alternative splicing can also produce vastly different protein isoforms for a given gene. The difference in protein sequence between isoforms suggests that the same gene can produce proteins with different and sometimes opposing functions. Indeed, there is evidence that different isoforms can have variable impacts on different developmental pathways. However, the ability to elucidate the different functions of distinct protein isoforms has proven difficult. For one, proteomic analysis has only been able to detect a small number of alternative protein isoforms, even when transcripts are present (Tress et al., 2017). This could be the result of the low abundance of alternative isoforms, especially since there is a high degree of tissue specificity in the expression of alternative protein isoforms (Morris et al., 2012; Gu et al., 2019; Rodriguez et al., 2020). Alternatively there could be mechanisms that reduce the rate of translation of certain alternative protein isoforms (Beerman and Jongens, 2011). Finally, in genes with more than one alternative protein isoform, few genetic tools, such as isoform-specific mutations, have been generated to properly elucidate the isoform-specific functions (Gu et al., 2019). Despite these challenges, several studies have been able to elucidate isoform-specific functions for select genes.

For example, the mouse kinesin family member 2A (Kif2a) gene, a microtubule depolymerizing kinesin, has three different protein isoforms. The isoforms are differentiated by the inclusion/exclusion of exon 18, encoding 37 amino acids, or the alternative 5′ site selection of exon 5, which alters the peptide sequence by 20 amino acids (Akkaya et al., 2021). Kif2a is known to be important for dendrite development and radial neuron migration. When coupling Kif2a shRNA knockdown with the inclusion of shRNA resistant cDNA of specific isoforms, all isoforms rescue aberrant dendritic morphology in Neuro2a cell culture. However, only the isoforms containing the long version of exon 5, KIF2A.1 and KIF2A.2, rescue radial migration defects of cortical neurons. Immunofluorescence imaging shows no significant difference in the localization of isoforms, suggesting any functional differences can be attributed to variations in protein sequence (Akkaya et al., 2021). Furthermore, proximity-labeling was used to identify isoform specific interactors. While KIF2A.1 and KIF2A.2 interactors were enriched with mitochondrial proteins, interactors of the isoform containing the short form of exon 5, KIF2A.3 were not. Furthermore, KIF2A.1 and KIF2A.2, but not KIF2A.3, co-localize with mitochondria, further supporting mitochondrial related functions for only a subset of the KIF2A protein isoforms (Akkaya et al., 2021).

There is also evidence to suggest that alternative splicing that results in the production of distinct protein isoforms is tissue specific. In one study that examined 255 alternative splice events, nearly 40% of the splicing events resulted in tissue-specific expression of an alternative protein isoform (Rodriguez et al., 2020). This tissue specificity is highlighted by the Drosophila Collapsin Response Mediator Protein (CRMP) gene. Immunofluorescence imaging of larvae with GFP-tagged protein isoforms that mutually exclude the amino acid sequences encoded by either exon 9a or 9b reveals that isoforms containing the protein sequence encoded by exon 9a are exclusively in non-neuronal tissue and those containing the protein sequence encoded by exon 9b are exclusively in neuronal tissue (Morris et al., 2012). Furthermore, the two different protein isoforms of the CRMP gene in Drosophila are orthologous to two entirely different genes in humans. The spliceform containing exon 9a is orthologous to human dihydropyrimidase (DPYS) and contains a conserved histidinyl residue important for pyrimidine catabolism. Conversely, the isoform containing exon 9b is
orthologous to human CRMP1. Additionally, using an assay to identify pyrimidine catabolism through the suppression of black pigmentation in black mutant animals, only flies with a functional isoform orthologous to human DPYS demonstrated functional pyrimidine catabolism. By contrast, flies with only a functional isoform orthologous to human CRMP1 did not appear to have functional pyrimidine catabolism (Morris et al., 2012).

The Transient receptor potential cation channel A1 (Trp1A) gene in Drosophila is another gene with multiple protein isoforms, produced through alternative splicing, that have distinct functions. Trp1A is an ion channel that detects noxious stimuli including heat, reactive oxygen species (ROS), UV light, and irritant chemicals (Gu et al., 2019). Trp1A is expressed in the larval midgut, corpus cardiacum cells, and within the nervous system. However, although there is some overlap in expression, the 5 alternative protein isoforms have distinct expression patterns from another (Gu et al., 2019). The variant isoforms are produced from the splicing of an alternative first exon and/or the splicing of mutually exclusive exons 12 and 13. Tissue specific knockdown of Trp1A using the Gal4-UAS system shows that Trp1A is necessary in Class IV dendritic arborization (C4da) neurons for nociceptive response to heat. The local administration of heat to larvae can stimulate a rolling behavior in what is termed a heat avoidance assay. This rolling behavior is lost when Trp1A is knocked down in C4da neurons. Interestingly, only 3 of the isoforms (C, D, and E) are expressed in C4da neurons (Gu et al., 2019). To examine the role of isoform specific expression in nociceptive behavior, transgenic lines that contained knock-ins of specific TRP1A protein isoforms in a Trp1A knock out background were developed and assessed using the heat avoidance assay. Only the knock-in of isoform D was able to rescue the nociceptive response in larvae, highlighting isoform specific functions of TRP1A in nociception (Gu et al., 2019). Additionally, Ca$^{2+}$ imaging showed C4da neuron activation in response to noxious heat only when isoform D was knocked in. Furthermore, an isoform specific transgenic line that simultaneously knocked out isoform A and D resulted in abolished rolling behavior, whereas knockout lines of the other isoforms were indistinguishable from wildtype (Gu et al., 2019). This suggests that both isoforms are capable of response to all the stimuli but may have varying degrees of sensitivity or a different threshold. Furthermore, overexpression of isoforms A, B, C, or D in a wildtype background resulted in heat allodynia, or the lowering of the heat threshold for nociceptive response suggesting all four isoforms may play a role in nociception. Interestingly, only isoform E did not have any observable function in nociception. This could suggest that isoform E is a non-functional byproduct of alternative splicing, or alternatively, that the function of isoform E has yet to be identified (Gu et al., 2019). Overall, the identification of tissue specific expression of protein isoforms coupled with functional differences among isoforms suggests that alternative splicing can be used to regulate protein structure to ensure protein functions that are tailored to a tissue’s unique and specific needs.

In Drosophila, the transcription factor longitudinals lacking (lola), has been shown to have 19 protein isoforms, all of which include four 5’ exons that encode the N-terminal BTB dimerization domain coupled with an alternatively spliced fifth exon (Goeke et al., 2003). 17 of the 19 isoforms also contain either a pair of zinc-finger domains or a single zinc-finger domain. Interestingly, alignment of the zinc-finger domains suggests that each of these 17 variants has different DNA contact residues. This implies that each variant could have distinct transcriptional targets (Goeke et al., 2003). Furthermore, RT-PCR revealed that distinct combinations of these spliceforms are expressed across various life stages and tissues. Finally, although dysfunction of lola has been demonstrated to cause CNS specific phenotypes and to also affect the development of the ISN₉ peripheral nerve, mutations specific to either the K or L isoforms impact development of the ISN₉ nerve with only mild effects on CNS function (Goeke et al., 2003). Taken together, this suggests while all Lola protein isoforms may function in transcriptional regulation, specific isoforms may regulate distinct targets during different developmental stages and tissues.

“Exon-activated functional rescue” (EXAR), in which specific alternative isoforms can rescue the activity of another gene, was recently described for the RBP, Found in Neurons (FNE), during Drosophila embryogenesis (Carrasco et al., 2020). The RBP encoded by embryonic lethal abnormal vision (elav) is important for the neuronal specific alternative cleavage and polyadenylation (APA) of multiple RNA targets (Carrasco et al., 2020). Interestingly, another protein of the ELAV-family, FNE, can compensate for certain ELAV functions. For example, neuronal APA is abolished in Δfne Δelav double mutants, but neuronal APA is not impacted in Δfne single mutants (Carrasco et al., 2020). Furthermore, in elav mutant animals, fne is alternatively spliced to include a mini-exon that is not expressed in wild-type Drosophila (Carrasco et al., 2020). The inclusion of the mini-exon increases the amino acid sequence similarity of ELAV and FNE between the second and third RNA recognition motifs, and facilitates nuclear localization of FNE, which is not observed in wildtype Drosophila. These changes confer the ability of FNE to carry out neuronal APA and therefore rescue ELAV function (Carrasco et al., 2020). Indeed, deletion of the mini-exon is sufficient to abolish nuclear localization of FNE in an elav mutant background and reduced the FNE-mediated rescue of neuronal APA (Carrasco et al., 2020). This data suggests that the presence of ELAV represses the inclusion of the fne mini-exon. However, in the absence of ELAV, the mini-exon is included resulting in the nuclear localization of FNE and the rescue of neuronal APA (Carrasco et al., 2020).

However, it is important to note that not all alternative protein isoforms result in differing functions. For example, Drosophila
**CONCLUSION**

It has long been recognized that the use of alternative splicing can generate different transcript isoforms from a single gene. Transcriptomic analyses have also begun to shed light on the tissue-specific, sex-specific and age-specific splicing patterns in various organisms. Future work will determine the extent to which these splicing patterns are conserved. Nonetheless, much remains to be learned with respect to the functions of different spliceforms. Historically, researchers have used the term “functional splicing” to describe the alternative splicing of RNAs to create distinct protein products. By contrast, isoforms that do not change the protein sequence and may instead be regulatory are referred to as “unproductive splicing” events. However, we suggest that this protein-centric terminology is rather misleading. Indeed, while alternative splicing of noncoding exons may not change the protein product of an mRNA spliceform, it can most certainly provide an important regulatory function. In fact, we have only just begun to appreciate the prominent impact of PE regulation in development and disease. Yet the recent link between aberrant PE regulation in cancer and neurological disorders provides promising avenues in developing novel therapeutic strategies. Thus, further research on the functional roles of PEs will increase our understanding of gene regulation and the genetic mechanisms underlying disease. Similarly, the observation that ALEs are differentially used in cancer and cell differentiation suggests that splicing of ALEs serves an important role within the cell and can ultimately affect protein function by regulating transcript localization. Thus, we propose instead to use the term “regulatory splicing”, as opposed to “unproductive” or “nonfunctional” splicing, to refer to the alternative splicing of noncoding exons that may affect the subcellular localization or stability of an RNA transcript. Moreover, a change in terminology should provide more accuracy and garner a greater awareness of the possible different functions that distinct spliceforms may have in the cell.

**AUTHOR CONTRIBUTIONS**

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

**FUNDING**

This work was funded through the National Institutes of Health awards NINDS 1 R15 NS104976 and NIA R03AG067071 to EO.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2021.775395/full#supplementary-material

**Supplementary Table S1** | List of NMD-sensitive or PTC-containing genes across Metazoa.

---

**REFERENCES**

Abouward, R., and Schiavo, G. (2021). Walking the Line: Mechanisms Underlying Directional mRNA Transport and Localization in Neurons and beyond. *Cell Mol. Life Sci.* 78, 2665–2681. doi:10.1007/s00018-020-03724-3

Adusumalli, S., Ngin, Z. K., Lin, W. Q., Benourkaf, T., and Ong, C. T. (2019). Increased Intron Retention Is a post-transcriptional Signature Associated with Progressive Aging and Alzheimer’s Disease. *Aging Cell* 18, e12928. doi:10.1111/agec.12928

Akkaya, C., Atak, D., Kamacioglu, A., Akaclar, B. A., Guner, G., Bayram, E., et al. (2021). Roles of Developmentally Regulated KIF2A Alternative Isoforms in Cortical Neuron Migration and Differentiation. *Dev. Cell* 148. doi:10.1016/j.devcel.2021.01.001

An, J. J., Gharami, K., Liao, G.-Y., Woo, N. H., Lau, A. G., Vanevski, F., et al. (2008). Distinct Role of Long 3′ UTR BDNF mRNA in Spine Morphology and Synaptic Plasticity in Hippocampal Neurons. *Cell* 134, 175–187. doi:10.1016/j.cell.2008.05.045

Ankó, M.-L., Müller-McNicol, M., Brandl, H., Curk, T., Gorup, C., Henry, I., et al. (2012). The RNA-Binding Landscapes of Two SR Proteins Reveal Unique Functions and Binding to Diverse RNA Classes. *Genome Biol.* 13, R17–R17. doi:10.1186/gb-2012-13-3-r17

Anthony, K., and Gallo, J.-M. (2010). Aberrant RNA Processing Events in Neurological Disorders. *Brain Res.* 1338, 67–77. doi:10.1016/j.brainres.2010.03.008

Aziz, M. C., Schneider, P. N., and Carvill, G. L. (2021). Targeting Poison Exons to Treat Developmental and Epileptic Encephalopathy. *Dev. Neurosci.* 43, 241–246. doi:10.1159/000516143

Bae, B., and Miura, P. (2020). Emerging Roles for 3′ UTRs in Neurons. *Ijms* 21, 3413. doi:10.3390/IJMS21103413

Baj, G., Leone, E., Chao, M. V., and Tongiorgi, E. (2011). Spatial Segregation of BDNF Transcripts Enables BDNF to Differentially Shape Distinct Dendritic
Sznajder, L. J., and Swanson, M. S. (2019). Short Tandem Repeat Expansions and RNA-Mediated Pathogenesis in Myotonic Dystrophy. Jnms 20, 3363. doi:10.3390/jnms20133365

Taliaferro, J. M., Vidaki, M., Oliveira, R., Olson, S., Zhan, L., Saxena, T., et al. (2016). Distal Alternative Last Exons Localize mRNAs to Neural Projections. Mol. Cell 61, 821–833. doi:10.1016/j.molcel.2016.01.020

Tazi, J., Bakkour, N., and Stamm, S. (20091792). Alternative Splicing and Disease. Biochim. Biophys. Acta (Bba) - Mol. Basis Dis. 1792, 14–26. doi:10.1016/j.bbadis.2008.09.017

Thomas, J. D., Polaski, J. T., Feng, Q., De Neef, E. J., Hoppe, E. R., McSharry, M. V., et al. (2020). RNA Isoform Screens Uncover the Essentiality and Tumor-Suppressor Activity of Ultraconserved Poison Exons. Nat. Genet. 52, 84–94. doi:10.1038/s41588-019-0555-z

Tower, J. (2017). Sex-Specific Gene Expression and Life Span Regulation. Trends Endocrinol. Metab. 28, 735–747. doi:10.1016/j.tem.2017.07.002

Tress, M. L., Abascal, F., and Valencia, A. (2017). Alternative Splicing May Not Be the Key to Proteome Complexity. Trends Biochem. Sci. 42, 98–110. doi:10.1016/j.tibs.2016.08.008

Ule, J., and Blencowe, B. J. (2019). Alternative Splicing Regulatory Networks: Functions, Mechanisms, and Evolution. Mol. Cell 76, 329–345. doi:10.1016/j.molcel.2019.09.017

Van Nostrand, E. L., Freese, P., Pratt, G. A., Wang, X., Wei, X., Xiao, R., et al. (2020). A Large-Scale Binding and Functional Map of Human RNA-Binding Proteins. Nature 583, 711–719. doi:10.1038/s41586-020-2077-3

Vaquero-Garcia, J., Barrera, A., Gazzara, M. R., Gonzalez-Vallinas, J., Lahens, N. F., Hogenesch, J. B., et al. (2016). A New View of Transcriptome Complexity and Regulation through the Lens of Local Splicing Variations. Elife 5. doi:10.7554/eLife.11752

Voskobiynych, Y., Battu, G., Felker, S. A., Cochran, J. N., Newton, M. P., Lambert, J. J., et al. (2021). Abrupt Regulation of a Poison Exon Caused by a Non-coding Variant in a Mouse Model of Scn1a-Associated Epileptic Encephalopathy. Plos Genet. 17, e1009195. doi:10.1371/journal.pgen.1009195

Wang, E. T., Sandberg, R., Luo, S., Khrebtukova, I., Zhang, L., Mayr, C., et al. (2008). Alternative Isoform Regulation in Human Tissue Transcriptomes. Nature 456, 470–476. doi:10.1038/nature07509

Wang, K., Wu, D., Zhang, H., Das, A., Basu, M., Malin, J., et al. (2018). Comprehensive Map of Age-Associated Splicing Changes across Human Tissues and Their Contributions to Age-Associated Diseases. Sci. Rep. 8, 1–12. doi:10.1038/s41598-018-29086-2

Weischenfeldt, J., Waage, J., Tian, G., Zhao, J., Damgaard, I., Jakobsen, J., et al. (2012). Mammalian Tissues Defective in Nonsense-Mediated mRNA Decay Display Highly Aberrant Splicing Patterns. Genome Biol. 13 (13), R35–R19. doi:10.1186/gb-2012-13-5-r35

Wittmann, J., Hol, E. M., and Jäck, H.-M. (2006). hUPF2 Silencing Identifies Physiologic Substrates of Mammalian Nonsense-Mediated mRNA Decay. Mol. Cell. Biol. 26, 1272–1287. doi:10.1128/MCB.26.1272-1287.2006

Xie, Z., Tang, L., Xie, Z., Sun, C., Shuai, H., Zhou, C., et al. (2020). Splicing Characteristics of Dystrophin Pseudoxons and Identification of a Novel Pathogenic Intrinsic Variant in the DMD Gene. Genes 11 (10), 1180. doi:10.3390/genes11101180

Yan, Q., Weyn-Vanheemynck, S. M., Wu, J., Sloan, S. A., Zhang, Y., Chen, K., et al. (2015). Systematic Discovery of Regulated and Conserved Alternative Exons in the Mammalian Brain Reveals NMD Modulating Chromatin Regulators. Proc. Natl. Acad. Sci. USA 112, 3445–3450. doi:10.1073/pnas.1502849112

Yergert, K. M., Doll, C. A., O’Rouke, R., Hines, J. H., and Appel, B. (2021). Identification of 3′ UTR Motifs Required for mRNA Localization to Myelin Sheaths In Vivo. Plos Biol. 19, e3001053. doi:10.1371/JOURNAL.PBIO.3001053

Zaghool, A., Niazi, A., Björklund, Å. K., Westholm, J. O., Ameer, A., and Feuk, L. (2021). Characterization of the Nuclear and Cytosolic Transcriptomes in Human Brain Tissue Reveals New Insights into the Subcellular Distribution of RNA Transcripts. Sci. Rep. 11. doi:10.1038/s41598-021-83541-1

Zeng, C., and Hamada, M. (2020). RNA-seq Analysis Reveals Localization-Associated Alternative Splicing Across 13 Cell Lines. Genes 11 (7), 820. doi:10.3390/genes11070820

Zhang, X., Chen, M. H., Wu, X., Kodani, A., Fan, J., Doan, R., et al. (2016). Cell-Type-Specific Alternative Splicing Governs Cell Fate in the Developing Cerebral Cortex. Cell 166, 1147–1162. doi:10.1016/j.cell.2016.07.025

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Titus, Chang and Olesnicky. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.